Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.32 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.32 |
| ▸ | FGF1 | P05230 | 2/20 | 0.31 |
| ▸ | FGF2 | P09038 | 2/20 | 0.31 |
| ▸ | VEGFA | P15692 | 2/20 | 0.31 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010882 | 1.00 | GJB2 (0.33) | GJB2SLC6A2SSTR1SSTR2SSTR4 | |
| SCHEMBL2011597 | 0.89 | GJB2 (0.32) | GJB2SLC6A2 | |
| SCHEMBL2011594 | 0.89 | GJB2 (0.32) | GJB2SLC6A2 | |
| SCHEMBL22821467 | 0.81 | SLC6A2 (0.34) | GJB2SLC6A2FGF1FGF2VEGFA | |
| SCHEMBL13424419 | 0.81 | BCHE (0.38) | SSTR1SSTR2SSTR4SSTR3SSTR5 | |
| SCHEMBL2006606 | 0.80 | SLC6A2 (0.37) | GJB2SLC6A2SSTR1SSTR2SSTR4 | |
| SCHEMBL2006603 | 0.80 | SLC6A2 (0.37) | GJB2SLC6A2SSTR1SSTR2SSTR4 | |
| SCHEMBL22050895 | 0.79 | PTPN1 (0.34) | GJB2FGF1FGF2VEGFAHPSE | |
| SCHEMBL8515951 | 0.74 | SLC6A2 (0.35) | GJB2SLC6A2SSTR1SSTR2SSTR4 | |
| SCHEMBL8515950 | 0.74 | SLC6A2 (0.35) | GJB2SLC6A2SSTR1SSTR2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074132-B1 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS INC (US) | 2013-05-15 | — | — | EP | disclosed |
| US-20120202762-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| EP-2457573-A1 | Methods of use of glycomimetics with replacements for hexoses and N-Acetyl hexosamines | GlycoMimetics, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| US-20110257380-A1 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | GLYCOMIMETICS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
| US-8026222-B2 | Use of oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated therein; treating inflammatory, vascular, and skin disorders such as diabetes, atherosclerosis, dermatitis, graft versus host disease, and lymphomas | GLYCOMIMETICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-7964569-B2 | Oligosaccharide mimetics such as {(1R,2R,3S)-2-[(6-Deoxy- alpha -L-Galactopyranosyl)Oxy]-3-Ethyl-Cyclohex-1-yl}2-O-Benzoyl-3-O-[(1S)-1-Carboxy-2-Cyclohexyl-Ethyl]- beta -D-Galactopyranoside | GLYCOMIMETICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20080200406-A1 | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines | GLYCOMIMETICS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080161546-A1 | Glycomimetic replacements for hexoses and N-acetyl hexosamines | GLYCOMIMETICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202762-A1 | METHODS OF USE OF GLYCOMIMETICS WITH REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | FUT6, ENGASE, FUT5 | GJB2 2182/4885SLC6A2 3383/4885SSTR1 2059/4885 |
| US-20080161546-A1 | Glycomimetic replacements for hexoses and N-acetyl hexosamines | FUT6, B3GNT2, FUT5 | GJB2 3890/4885SLC6A2 3382/4885SSTR1 2170/4885 |
| US-20110257380-A1 | GLYCOMIMETIC REPLACEMENTS FOR HEXOSES AND N-ACETYL HEXOSAMINES | FUT6, B3GNT2, FUT5 | GJB2 3890/4885SLC6A2 3382/4885SSTR1 2170/4885 |
| US-20080200406-A1 | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines | FUT6, ENGASE, FUT5 | GJB2 2182/4885SLC6A2 3383/4885SSTR1 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.